Featured Research

from universities, journals, and other organizations

Molecular disease model for melanoma

Date:
March 30, 2011
Source:
Public Library of Science
Summary:
A new molecular disease model of melanoma classifies the disease into molecular subtypes, rather than traditional histological or cellular subtypes, and describes treatment guidelines for each subtype, including specific assays, drugs, and clinical trials.

Cancer Commons, an initiative of CollabRx, a provider of information technology to personalize cancer treatments and accelerate research, announces the publication of a molecular disease model of melanoma (MDMM) which classifies the disease into molecular subtypes, rather than traditional histological or cellular subtypes, and describes treatment guidelines for each subtype, including specific assays, drugs, and clinical trials.

Related Articles


Published as a "dynamic" review paper by a panel of leading researchers and clinicians affiliated with the Cancer Commons initiative, the MDMM is maintained online, curated by the authors and continuously updated based on input from the melanoma community to reflect the latest scientific, clinical and technological advancements in cancer research and treatment. The MDMM is designed as an interface between the research and clinical communities where researchers can learn from clinical outcomes to refine molecular subtypes and clinicians can use the latest subtype information in treatment decisions. In this way, the online melanoma disease model becomes the core of an adaptive, rapid learning community that provides each patient with the best possible outcome while aggregating results over all patients to advance the standard of care.

The MDMM consists of a set of "actionable" molecular subtypes and proposed practice guidelines for treating each subtype: which therapies (approved or experimental) should be considered and which are contraindicated. A molecular subtype of melanoma is loosely defined as those tumors containing the same set of molecular (primarily genetic) defect(s) and their associated pathways. A subtype is deemed actionable if there is both a CLIA-approved assay to determine whether a given tumor fits that classification, and at least one FDA-approved or experimental targeted therapy with potential efficacy for that subtype.

Commented Dr. Keith Flaherty, Director of Developmental Therapeutics at Massachusetts General Hospital and co-chief editor of Cancer Commons Melanoma: "While earlier stages of melanoma can be successfully treated by surgical excision, advanced stages are uniquely refractory to standard chemotherapy. Recent developments in our understanding of the molecular drivers of this disease have led to a new generation of targeted therapies that are proving effective in patients whose tumors harbor certain genetic defects. Rather than treating melanoma as a single disease, it makes sense to stratify tumors into molecular subtypes and treat each with the most appropriate therapies."

The molecular disease model for melanoma is the first of many such models planned by Cancer Commons, the open science initiative for personalized oncology that was initially convened by CollabRx. Cancer Commons is creating a network of rapid learning communities where physicians, scientists, and patients collaborate to provide each patient with the best possible outcome by personalizing therapy based on the tumor's genomic subtype. CollabRx is developing web-based applications and services that facilitate this collaboration; the first of these, The Targeted Therapy Finder -- Melanoma, leverages the MDMM to find treatments targeted to a patient's specific molecular profile.

Funding: SJV, JMT, MDT and JS are or were employees of CollabRx, Inc. a for-profit corporation. They played intimate roles in the research and preparation of the manuscript.


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Smruti J. Vidwans, Keith T. Flaherty, David E. Fisher, Jay M. Tenenbaum, Michael D. Travers, Jeff Shrager. A Melanoma Molecular Disease Model. PLoS ONE, 2011; 6 (3): e18257 DOI: 10.1371/journal.pone.0018257

Cite This Page:

Public Library of Science. "Molecular disease model for melanoma." ScienceDaily. ScienceDaily, 30 March 2011. <www.sciencedaily.com/releases/2011/03/110330192214.htm>.
Public Library of Science. (2011, March 30). Molecular disease model for melanoma. ScienceDaily. Retrieved January 26, 2015 from www.sciencedaily.com/releases/2011/03/110330192214.htm
Public Library of Science. "Molecular disease model for melanoma." ScienceDaily. www.sciencedaily.com/releases/2011/03/110330192214.htm (accessed January 26, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, January 26, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Mistakes Should Serve a Lesson Says WHO

Ebola Mistakes Should Serve a Lesson Says WHO

AFP (Jan. 25, 2015) The World Health Organization&apos;s chief on Sunday admitted the UN agency had been caught napping on Ebola, saying it should serve a lesson to avoid similar mistakes in future. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Disneyland Measles Outbreak Spreads To 5 States

Disneyland Measles Outbreak Spreads To 5 States

Newsy (Jan. 24, 2015) Much of the Disneyland measles outbreak is being blamed on the anti-vaccination movement. The CDC encourages just about everyone get immunized. Video provided by Newsy
Powered by NewsLook.com
Growing Measles Outbreak Worries Calif. Parents

Growing Measles Outbreak Worries Calif. Parents

AP (Jan. 23, 2015) Public health officials are rushing to contain a measles outbreak that has sickened 70 people across 6 states and Mexico. The AP&apos;s Raquel Maria Dillon has more. (Jan. 23) Video provided by AP
Powered by NewsLook.com
Smart Wristband to Shock Away Bad Habits

Smart Wristband to Shock Away Bad Habits

Reuters - Innovations Video Online (Jan. 23, 2015) A Boston start-up is developing a wristband they say will help users break bad habits by jolting them with an electric shock. Ben Gruber reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins